Splash Beverage entered a Development and Collaboration Agreement with Lupvindol to lead FDA regulatory work for a cannabinoid-based veterinary drug derived from CannEpil. The plan covers INAD initiation, studies, and filing for conditional approval, with Splash funding milestones totaling up to $1…
Splash Beverage Group entered into an addendum to its exclusive global license for CannEpil to include veterinary applications. The amendment sets a 10% royalty on net revenue from veterinary uses and a 15% royalty for human applications, and extends certain deadlines under the original license. Ma…
FORT LAUDERDALE, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American:SBEV ("Splash," "Splash Beverage" or the "Company") today announced two significant actions designed to strengthen the Company's financial position and advance its previously announced NYSE American…
Splash Beverage Group entered into a letter agreement to settle its obligations under a prior Revenue Loan and Security Agreement. By paying $301,800.55 on or before Aug 31, 2026, the company can satisfy outstanding obligations totaling $2,834,689. Upon timely payment, the lender will release Splas…
